Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Results of Phase II study of tislelizumab in R/R NK/T-cell neoplasms

Emmanuel Bachy, MD, PhD, Lyon Sud Hospital Center, Lyon, France, outlines the results of a Phase II study evaluating the safety and efficacy of tislelizumab in patients with relapsed/refractory (R/R) NK/T-cell lymphoma, peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) (NCT03493451). The trial reported a promising overall response rate (ORR) in patients with CTCL but not in patients with PTCL and NK/T-cell lymphoma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.